#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Athero Review / 2018 - 3

Atherosclerosis in cancer patients

Czech version

Authors: Beata Mladosievičová
Authors‘ workplace: Oddelenie klinickej patofyziológie, LF UK v Bratislave
Published in: AtheroRev 2018; 3(3): 179-183
Category: Reviews

Overview

Atherosclerosis induced by conventional anticancer drugs and radiotherapy have been a relevant issue of cancer patients during last decade. In addition, targeted and androgen-deprivation therapies can also induce vascular damage in these patients. Immune checkpoint inhibitors are a novel class of effective antineoplastic drugs with cardiotoxicity used in patients with malignancies. Atherosclerotic damage has been long underestimated in clinical practice, but recently a significant number of patients with serious artery disease during or after completion of anticancer therapy have been reported. Here we describe atherosclerosis induced by selected prominent drugs and radio­therapy used in oncology which have received particular attention in recent years. Additionally, this article presents common risk factors for cancer and atherosclerosis. It deals also with inflammation triggered by cancer.

Key words:

ateroskleróza, kardioonkológia , kardiotoxicita, kardiovaskulárne ochorenia, neskorá toxicita, rizikové faktory, zápal

Received: 4. 9. 2018

Accepted: 1. 10. 2018

Sources
  1. Mladosievičová B et al. Kardioonkologie. 2. vyd. Grada: Praha 2014. ISBN 978–80–247–4838–2.
  2. Zamorano JL, Lancellotti P, Rodriguez et al. ESC Committee for Practice Guidelines (CPG). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the aus¬pices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(36): 2768–2801. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw211>. Erratum in Corrigendum. [Eur Heart J. 2018].
  3. Herrmann J, Yang EH, Iliescu CA et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation 2016; 133(13): 1272–1289. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018347>.
  4. Vohnout B, Rašlová K. Rizikové faktory rozvoja aterisklerózy: lipidy a ich vzťah k ateroskleróze. Via Pract 2009; 6(3): 116–119.
  5. Koene RJ, Prizment AF, Blaes A et al. Shared risk factors in cardiovascular disease and cancer. Circulation 2016; 133(11): 1104–1114. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020406>.
  6. Masoudkabir F, Sarrafzadegan N, Gotay C et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis 2017; 263: 343–351. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.001>.
  7. Giza DE, Iliescu G, Hassan S et al. Cancer as a risk factor for cardiovascular disease. Curr Oncol Rep 2017; 19(6): 39. Dostupné z DOI: <http://dx.doi.org/10.1007/s11912–017–0601-x>.
  8. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355(9209): 1075–1076.
  9. Chovanec M, Abu Zaid M, Hanna N et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 2017;28(11): 2670–2679. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdx360>.
  10. Valentová M, Mladosievicová B. Coronary heart disease and hypertension as late effects of testicular cancer treatment – a minireview. Klin Onkol 2011; 24(1): 18–22.
  11. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol Apr; 18(8): 1725–1732. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2000.18.8.1725>.
  12. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24(27): 4448–4456. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2006.06.2497>.
  13. Greiman AK, Keane TE. Approach to androgen deprivation in the prostate cancer patient with pre-existing cardiovascular disease. Curr Urol Rep 2017; 18(6): 41. Dostupné z DOI: <http://dx.doi.org/10.1007/s11934–017–0688–5>.
  14. Poljak Z, Hulin I, Maruscakova L et al. Androgen deprivation therapy and cardiovascular complications. Bratisl Lek Listy 2016; 117(10): 557–561. Dostupné z DOI: <http://dx.doi.org/10.4149/BLL_2016_109>.
  15. Carneiro A, Sasse AD, Wagner AA et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol 2015; 33(9): 1281–1289. Dostupné z DOI: <http://dx.doi.org/10.1007/s00345–014–1439–6>.
  16. Albertsen PC. Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists. Eur J Cancer 2017; 87: 203. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejca.2017.06.041>.
  17. Sternberg CN, Castellano D, Daugaard G et al.Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol 2014; 15(11): 1263–1268. Dostupné z DOI: <http://dx.doi.org/10.1016/S1470–2045(14)70417–6>. Erratum in Lancet Oncol 2014; 15(12): e528.
  18. Campora S, Campazzi E, Zanardi S et al. Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. Transl Oncol 2016; 9(6): 600–605. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tranon.2016.08.001>.
  19. Cutter DJ, Darby SC, Yusuf SW. Risks of heart disease after radiotherapy. Tex Heart Inst J 2011; 38(3): 257–258.
  20. Mehta LS, Watson KE, Barac A et al. [American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research]. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation 2018;137(8):e30-e66. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000556>.
  21. Girinsky T, M‘Kacher R, Lessard N et al. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis. Int J Radiat Oncol Biol Phys 2014; 89(1): 59–66. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijrobp.2014.01.021>.
  22. Darby SC, Ewertz M, Hall P. Ischemic heart disease after breast cancer radiotherapy. N Engl J Med 2013; 368(26): 2527. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMc1304601>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Fibrates in 2018: story goes on
Statins, brain and cholesterol: is it going together?
Anorexia nervosa and lipid metabolism disorders
Atherosclerosis and cardial autonomic nervous system
Lysosomal storage disorders as the cause of dyslipoproteinemia
Pictures of plaques and fixed drug combination for better cardiovascular prevention
Fixed-combination of rosuvastatin with ezetimibe in the treatment of secondary prevention patient
Consensus statement of professional associations on prescribing of PCSK9-inhibitors
Open questions from cardiovascular studies FOURIER and ODYSSEY Outcomes
Article was published in

Athero Review

Issue 3
2018 Issue 3
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#